The TÜBİTAK 1007 project is a large budget, multidisciplinary collaborative project, whose ultimate aim is the development, licensing and commercialization of the biosimilars for a monoclonal antibody that is currently licensed as a biotherapeutic drug in USA and EU countries. Several research groups in DEU iBG-izmir as well as researchers from Dokuz Eylul University are involved in different workpackages of this project, which will be carried out in partnership with a Turkish pharma company.

The project has commenced on 10th of February 2017 with a kick-off meeting that took place in TUBITAK headquarters in Ankara. Major researchers involved in the project, representatives from TUBITAK and Turkish Ministry of Health and independent observers were brought together to discuss the details of the work to be performed.